7. Conclusions
After more than fifteen years, the often lively and contradictory scientific reflections and discussions carried out by international and national multidisciplinary groups have led to the adoption of a comparative methodological approach for assessing the safety of GM plants.
No publication whose protocol and/or results are recognized by the scientific community has been able to provide proof of a proven risk from GMPs that are the subject of an application for authorization to grow or market. The assessments carried out allow us to conclude that these GMPs pose no more health problems than the conventional foods with which they can be compared. A fairly comprehensive presentation of the data obtained can be found in the EFSA report .
Questions remain, however, concerning the safety assessment not only of GMPs, but of all...
The Ultimate Scientific and Technical Reference
This article is included in
Safety and risk management
This offer includes:
Knowledge Base
Updated and enriched with articles validated by our scientific committees
Services
A set of exclusive tools to complement the resources
Practical Path
Operational and didactic, to guarantee the acquisition of transversal skills
Doc & Quiz
Interactive articles with quizzes, for constructive reading
Conclusions
Economic data
In 2007, GMPs were grown on more than 114 million hectares worldwide (figure ); 101 Mha on the American continent, around 6 Mha in India and 4 Mha in China, and very few in Europe (less than 300,000 ha, including 100,000 ha in Spain and Romania, and around 22,000 ha in France). In 2007, therefore, these GMPs were field crops grown in major agricultural countries.
Image 7 error...
Bibliography
Websites
FAO
http://www.fao.org/ag/agn/agns/biotechnology_en.asp
WHO
http://www.who.int/foodsafety/biotech/en/
EFSA
The Ultimate Scientific and Technical Reference
